FFAR4-mediated IL-6 release from islet macrophages promotes insulin secretion and is compromised in type-2 diabetes

Xinyi Chen, Jingchen Shao, Isabell Brandenburger, Weikun Qian, Lisa Hahnefeld, Rémy Bonnavion, Haaglim Cho, ShengPeng Wang, Juan Hidalgo, Nina Wettschureck, Gerd Geisslinger, Robert Gurke, Zheng Wang and Stefan Offermanns ()
Additional contact information
Xinyi Chen: Department of Pharmacology
Jingchen Shao: Department of Pharmacology
Isabell Brandenburger: Department of Pharmacology
Weikun Qian: Pancreas Center of Xi’an Jiaotong University
Lisa Hahnefeld: Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP) and Fraunhofer Cluster of Excellence for Immune Mediated Diseases (CIMD)
Rémy Bonnavion: Department of Pharmacology
Haaglim Cho: Department of Pharmacology
ShengPeng Wang: The First Affiliated Hospital of Xi’an Jiaotong University. Xi’an
Juan Hidalgo: Autonomous University of Barcelona
Nina Wettschureck: Department of Pharmacology
Gerd Geisslinger: Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP) and Fraunhofer Cluster of Excellence for Immune Mediated Diseases (CIMD)
Robert Gurke: Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP) and Fraunhofer Cluster of Excellence for Immune Mediated Diseases (CIMD)
Zheng Wang: Pancreas Center of Xi’an Jiaotong University
Stefan Offermanns: Department of Pharmacology

Nature Communications, 2025, vol. 16, issue 1, 1-14

Abstract: Abstract The function of islet macrophages is poorly understood. They promote glucose-stimulated insulin secretion (GSIS) in lean mice, however, the underlying mechanism has remained unclear. We show that activation of the free fatty acid receptor FFAR4 on islet macrophages leads to interleukin-6 (IL-6) release and that IL-6 promotes β-cell function. This mechanism is required for GSIS in lean male mice, but does not function anymore in islets from people with obesity and obese type 2 diabetic male mice. In islets from obese mice, FFAR4 downstream signaling in macrophages is strongly reduced, resulting in impaired FFAR4-mediated IL-6 release. However, IL-6 treatment can still improve GSIS in islets from people with obesity and obese type 2 diabetic mice. These data show that a defect in FFAR4-mediated macrophage activation contributes to reduced GSIS in type 2 diabetes and suggest that reactivating islet macrophage FFAR4 and promoting or mimicking IL-6 release from islet macrophages improves GSIS in type 2 diabetes.

Date: 2025
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-58706-5 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-58706-5

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-58706-5

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().